The 10-day moving average for REGN crossed bullishly above the 50-day moving average on October 26, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 12 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 80%.
The Momentum Indicator moved above the 0 level on October 12, 2026. You may want to consider a long position or call options on REGN as a result. In 56 of 91 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 62%.
The Moving Average Convergence Divergence (MACD) for REGN just turned positive on October 14, 2026. Looking at past instances where REGN's MACD turned positive, the stock continued to rise in 34 of 50 cases over the following month. The odds of a continued upward trend are 68%.
REGN moved above its 50-day moving average on October 20, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +4.90% 3-day Advance, the price is estimated to grow further. Considering data from situations where REGN advanced for three days, in 202 of 314 cases, the price rose further within the following month. The odds of a continued upward trend are 64%.
The Aroon Indicator entered an Uptrend today. In 186 of 265 cases where REGN Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 70%.
The 10-day RSI Indicator for REGN moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 41 similar instances where the indicator moved out of overbought territory. In 16 of the 41 cases, the stock moved lower in the following days. This puts the odds of a move lower at 39%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 43 of 65 cases where REGN's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 66%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where REGN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 57%.
REGN broke above its upper Bollinger Band on October 30, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron Price Growth Rating for this company is 7 (best 1 - 100 worst), indicating outstanding price growth. REGN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 13 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 59 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 65 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock slightly better than average.
The Tickeron Valuation Rating of 88 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.936) is normal, around the industry mean (3.498). P/E Ratio (21.599) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (1.238) is also within normal values, averaging (9.059). Dividend Yield (0.004) settles around the average of (130.981) among similar stocks. P/S Ratio (5.339) is also within normal values, averaging (440.869).
TBXU saw its Momentum Indicator move above the 0 level on October 15, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 13 similar instances where the indicator turned positive. In 12 of the 13 cases, the stock moved higher in the following days. The odds of a move higher are at 90%.
The Moving Average Convergence Divergence (MACD) for TBXU just turned positive on October 15, 2026. Looking at past instances where TBXU's MACD turned positive, the stock continued to rise in 8 of 9 cases over the following month. The odds of a continued upward trend are 89%.
TBXU moved above its 50-day moving average on October 21, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for TBXU crossed bullishly above the 50-day moving average on October 29, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 2 of 2 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.
Following a +8.87% 3-day Advance, the price is estimated to grow further. Considering data from situations where TBXU advanced for three days, in 41 of 46 cases, the price rose further within the following month. The odds of a continued upward trend are 89%.
The Aroon Indicator entered an Uptrend today. In 48 of 56 cases where TBXU Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 86%.
The 10-day RSI Indicator for TBXU moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 12 similar instances where the indicator moved out of overbought territory. In 10 of the 12 cases, the stock moved lower in the following days. This puts the odds of a move lower at 83%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 12 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
TBXU broke above its upper Bollinger Band on October 30, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
REGN | ||
|---|---|---|
OUTLOOK RATING 1..100 | 50 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 88 Overvalued | |
PROFIT vs RISK RATING 1..100 | 65 | |
SMR RATING 1..100 | 59 | |
PRICE GROWTH RATING 1..100 | 7 | |
P/E GROWTH RATING 1..100 | 13 | |
SEASONALITY SCORE 1..100 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
| REGN | TBXU | |
|---|---|---|
| RSI ODDS (%) | 4 days ago 39% | 4 days ago 83% |
| Stochastic ODDS (%) | 4 days ago 66% | 4 days ago 88% |
| Momentum ODDS (%) | 4 days ago 62% | 4 days ago 90% |
| MACD ODDS (%) | 4 days ago 68% | 4 days ago 89% |
| TrendWeek ODDS (%) | 4 days ago 57% | 4 days ago 87% |
| TrendMonth ODDS (%) | 4 days ago 65% | 4 days ago 88% |
| Advances ODDS (%) | 7 days ago 64% | 8 days ago 89% |
| Declines ODDS (%) | 5 days ago 57% | N/A |
| BollingerBands ODDS (%) | 4 days ago 51% | 4 days ago 78% |
| Aroon ODDS (%) | 4 days ago 70% | 4 days ago 86% |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
REGN’s FA Score shows that 2 FA rating(s) are green while .
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
REGN’s TA Score shows that 6 TA indicator(s) are bullish.
REGN (@Biotechnology) experienced а -2.54% price change this weekfor the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +2.97%. For the same industry, the average monthly price growth was -8.33%, and the average quarterly price growth was +85.08%.
REGN is expected to report earnings on Jan 29, 2027.
Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
A.I.dvisor indicates that over the last year, TBXU has been closely correlated with AMGN. These tickers have moved in lockstep 69% of the time. This A.I.-generated data suggests there is a high statistical probability that if TBXU jumps, then AMGN could also see price increases.
| Ticker / NAME | Correlation To TBXU | 1D Price Change % | ||
|---|---|---|---|---|
| TBXU | 100% | +1.49% | ||
| AMGN - TBXU | 69% Closely correlated | +0.03% | ||
| VRTX - TBXU | 68% Closely correlated | +0.85% | ||
| REGN - TBXU | 63% Loosely correlated | +0.16% | ||
| GILD - TBXU | 62% Loosely correlated | -0.41% | ||
| ARGX - TBXU | 49% Loosely correlated | +3.63% |
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| KRWX | 7.80 | 0.24 | +3.22% |
| Corgi South Korea 2x Daily ETF (KRWX) | |||
| FOCT | 53.39 | 0.11 | +0.21% |
| FT Vest US Equity Buffer ETF - October | |||
| SSK | 12.13 | N/A | N/A |
| REX-Osprey SOL + Staking ETF (SSK) | |||
| DFII | 12.73 | -0.05 | -0.36% |
| Ft Vest Bitcoin Strategy & Target Income ETF | |||
| AMZU | 35.84 | -0.38 | -1.05% |
| Direxion Daily AMZN Bull 2X ETF (AMZU) | |||